CBG-002

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCBG-002
Drug Alias Nameanti-BCMA CAR T-cell therapy (Carbiogene Therapeutics)CBG-002
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulators
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCarbiogene Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCarbiogene Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A